Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer

New targeted therapies are needed for advanced thyroid cancer. Our lab has shown that Src is a key mediator of tumorigenic processes in thyroid cancer. However, single-agent Src inhibitors have had limited efficacy in solid tumors. In order to more effectively target Src in the clinic, our lab has p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishall, Katie M., Beadnell, Thomas C., Kuenzi, Brent M., Klimczak, Dorothy M., Superti-Furga, Giulio, Rix, Uwe, Schweppe, Rebecca E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732707/
https://www.ncbi.nlm.nih.gov/pubmed/29262541
http://dx.doi.org/10.18632/oncotarget.20488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732707/
https://www.ncbi.nlm.nih.gov/pubmed/29262541
http://dx.doi.org/10.18632/oncotarget.20488

Ejemplares similares